Euro Biotechnology

Click to view a price quote on SAGE.

Click to research the Drugs industry.

[Source: Research & Innovation] A hydropower research conference will take place in Brussels on 8 November 2018. The event will offer an opportunity to discuss the impacts of R&D funded through the EU Framework Programmes for Research and Innovation. It will present the Hydropower R&D Impact Report and recommendations to increase future R&D impacts. In addition key industry experts will share their insights on the future of hydropower technologies and there will be opportunities to discuss the impacts of your own research projects.

Each year BIO brings the patient stakeholder community together for the BIO Patient and Health Advocacy Summit to network; to learn; to engage; to partner; and to discover.

Held this year-its seventh-at the Park Hyatt hotel in Washington, DC, the Summit concluded today after running a robust program focused squarely on patients and their immeasurable contributions to the drug development process.

The two days of educational panels addressed best practices for engaging with industry, patient access to life-saving medicines, the opioid crisis, the FDA’s “Patient-Focused Drug Development” guidance and the Trump Administration’s “American Patients First Blueprint”-a proposed plan for addressing the cost of prescription drugs. Two of the sessions were live streamed on Facebook.

The intimate setting for the event was perfect for the lunchtime roundtable discussions hosted by subject matter experts from drug development companies and BIO staff. Attendees could choose from among 12 different subject areas which included such diverse topics as unconscious bias in clinical research, genome editing, Medicare Part B access and newborn screening-to name a few.

BIO’s One-on-one Partnering™ offered attendees individual meetings with potential collaborators, patient groups, industry reps and other stakeholders. This more targeted networking opportunity helped participants connect with the right people, enhancing their chances for building alliances that address unmet medical needs.

We talked with several attendees about their experience at the summit.

“If you look at who they’ve targeted so far, it’s almost like they’re following Donald Trump’s Twitter feed,” said former Hillary Clinton adviser Philippe …

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: REC-AG-2018Pillar: REC Programme 2014-2020Opening Date: Deadline: Thu, 27 Sep 2018 17:00:00 (Brussels local time)Modification Date: Thu, 25 Oct 2018Latest information: Un updated version of Questions and Answers document has been added under Topic conditions and documents, Additional documents.

The winner of the largest-ever startup pitch contest in San Diego is aiming to solve a problem that is weighing heavily on the national consciousness.

The same day President Trump signed a bipartisan package of measures to address the opioid epidemic, San Diego startup NeuraLace Medical won $50,000 on Wednesday at the annual John G. Watson Quick Pitch Competition to further the development of its nerve pain management device.

The White House said the legislation passed Wednesday, is intended to reduce the supply of and access to opioids and expand access to prevention, treatment, and recovery services.

The Centers for Disease… Read more »

Reprints | Share:          

UNDERWRITERS AND PARTNERS

[Updated 4:15pm ET with pharma industry trade group comment, see below.] When the Trump administration announced its blueprint for lowering prescription drug prices in May, many observers said it was too soft on the biopharma industry and didn’t contain concrete initiatives that could truly cut costs.

But with the U.S. midterm elections fast approaching and the high cost of drugs and healthcare remaining a key issue with voters of both political parties, President Trump today announced some more aggressive moves, starting with a plan to lower prices for some drugs covered by Medicare.

After much rhetoric from Trump… Read more »

Reprints | Share:          

UNDERWRITERS AND PARTNERS

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: ERC-2019-COGPillar: Excellent ScienceOpening Date: Deadline: Thu, 7 Feb 2019 17:00:00 (Brussels local time)Modification Date: Thu, 25 Oct 2018Latest information: The submission session is now available for: ERC-2019-COG(ERC-COG)

Leading researchers representing more than 85 European plant and life sciences research centres and institutes have endorsed a position paper that urgently calls upon European policy makers to safeguard gene-editing technologies in plant science and agriculture.

The scientists are deeply concerned about a recent European Court of Justice ruling concerning modern genome editing techniques that could lead to a de facto ban of innovative crop breeding.

The position paper argues the European farmers may be deprived of a new generation of more climate resilient and nutritious crop varieties that are urgently needed to respond to current ecological and societal challenges.

The joint document follows an outpouring of concerned statements of European research institutes over the recent months following the Court of Justice of the European Union (ECJ) ruling under which genome edited organisms must comply with strict EU Genetically Modified Organisms (GMO) legislation.

The position paper is evidence of a solid consensus among the academic life science research community in Europe on the negative consequences of the ruling.

“The support for this initiative from plant scientists all over Europe has been overwhelming,” said Dirk Inzé, scientific director at VIB-University of Gent Centre for Plant Systems Biology and one of the initiators of the position paper.

“It clearly illustrates the current dichotomy in Europe: as European leaders in the field of plant sciences we are committed to bringing innovative and sustainable solutions to agriculture, but we are hindered by an outdated regulatory framework that is not in line with recent scientific evidence. With this mission statement we hope to promote evidence-informed policymaking in the EU, which is of crucial importance to us all.”

– Dirk Inzé, scientific director at VIB-University of Gent Centre for Plant Systems Biology

The implications of a very restrictive regulation of innovative plant breeding methods are far-reaching, say the signatories, arguing that European agricultural innovation based on precision breeding will come to a halt because of the high threshold that this EU legislation presents.

To safeguard innovation in agriculture in Europe, the signatories of the position paper ask for a new regulatory framework that evaluates new crop varieties based on science.

Readers can view the position paper and add your name to the list of signatories here. ​

[Source: http://ec.europa.eu/health/ageing/innovation/index_en.htm] Identifier: ISFP-2018-AG-SCHENPillar: Police cooperationOpening Date: Deadline: Thu, 2 May 2019 17:00:00 (Brussels local time)Modification Date: Thu, 25 Oct 2018Latest information: The submission session is now available for: ISFP-2018-AG-SCHEN(ISFP-AG)